Literature DB >> 3527495

Eicosanoids and their role in the pathogenesis of diarrhoeal diseases.

J Rask-Madsen.   

Abstract

Eicosanoids are unsaturated fatty acid compounds derived from 20-carbon 'essential' fatty acids, the most important being arachidonate. Both cyclooxygenase and lipoxygenase products of arachidonate are abundant in the human gut and their biological effects include modulation of fluid and electrolyte secretion, motor activity, mucosal blood flow, and cytoprotection, in addition to chemotaxis and immune response in inflammation. In health, these lipid mediators reinforce or synergize normal homeostatic mechanisms that could proceed in their absence. Receptors for control of intestinal secretion can be divided into two major classes, one of which triggers the production of cyclic AMP and another, which initiates phospholipid breakdown and arachidonate release. An intimate connection appears to exist between phospholipid metabolism, cytosolic Ca2+ levels, electrogenic anion secretion, Na+ pump rate, electroneutral Na+/H+ exchange activity, and intracellular pH. Ca2+-dependent secretagogues affect fluid and electrolyte transport in the small and the large bowel by increasing Ca2+ entry and Ca2+ mobilization through stimulation of eicosanoid formation, prostaglandins of the E type being the most important. Secretory diarrhoea may be thought of, therefore, as cellular Ca2+ intoxication. Uncontrolled formation of eicosanoids, perhaps with a changed spectrum of arachidonate metabolites, may not only be the source of diarrhoea associated with mucosal inflammation, but may also be critical for cell proliferation resulting in abnormal cell differentiation, which seems to be the link between long-standing inflammatory bowel disease and the increased risk of colonic neoplasia. A better understanding of the pathophysiological role of eicosanoids in diarrhoeal disease has allowed reinterpretation of the rationale behind current therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527495

Source DB:  PubMed          Journal:  Clin Gastroenterol        ISSN: 0300-5089


  10 in total

Review 1.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

2.  Prostaglandin E2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum.

Authors:  L K Munck; A Mertz-Nielsen; H Westh; K Bukhave; E Beubler; J Rask-Madsen
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

3.  Inhibition of attaching and effacing lesion formation following enteropathogenic Escherichia coli and Shiga toxin-producing E. coli infection.

Authors:  K Johnson-Henry; J L Wallace; N S Basappa; R Soni; G K Wu; P M Sherman
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Roles of leukotriene B4, prostaglandin E2, and cyclic AMP in Campylobacter jejuni-induced intestinal fluid secretion.

Authors:  P H Everest; A T Cole; C J Hawkey; S Knutton; H Goossens; J P Butzler; J M Ketley; P H Williams
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion.

Authors:  T D Wardle; L Hall; L A Turnberg
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

6.  Source of endogenous arachidonate and 5-lipoxygenase products in human neutrophils stimulated by bradykinin and A23187.

Authors:  O H Nielsen; K Bukhave; I Ahnfelt-Rønne; J Rask-Madsen
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

7.  Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase. Clinical implications.

Authors:  J M Pawlotsky; P Ruszniewski; F Reyl-Desmars; M Bourgeois; M J Lewin
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

8.  Fluid secretion caused by aerolysin-like hemolysin of Aeromonas sobria in the intestines is due to stimulation of production of prostaglandin E2 via cyclooxygenase 2 by intestinal cells.

Authors:  Yoshio Fujii; Ken Tsurumi; Masaaki Sato; Eizo Takahashi; Keinosuke Okamoto
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

9.  Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach.

Authors:  Qiong Wang; Zhigang Zhao; Jing Shang; Wei Xia
Journal:  J Diabetes Res       Date:  2014-10-21       Impact factor: 4.011

Review 10.  Mechanisms of diarrhoea.

Authors:  I W Booth; A S McNeish
Journal:  Baillieres Clin Gastroenterol       Date:  1993-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.